IL-2 detected by flow cytometry and its significance in systemic lupus erythematosus.

IF 2.9 3区医学 Q2 RHEUMATOLOGY

Clinical Rheumatology Pub Date : 2025-05-22 DOI:10.1007/s10067-025-07478-w

Yingni Li, Tingting Wang, Yuzhou Gan, Xia Zhang, Leixi Xue, Boyi Xu, Xiaolin Sun, Zhanguo Li

{"title":"IL-2 detected by flow cytometry and its significance in systemic lupus erythematosus.","authors":"Yingni Li, Tingting Wang, Yuzhou Gan, Xia Zhang, Leixi Xue, Boyi Xu, Xiaolin Sun, Zhanguo Li","doi":"10.1007/s10067-025-07478-w","DOIUrl":null,"url":null,"abstract":"Objective: Low-dose interleukin 2 (IL-2) administration has been shown to selectively modulate regulatory T (Treg) cell abundance and alleviate the progression of systemic lupus erythematosus (SLE). IL-2 level could be indicator of low-dose IL-2 usage in SLE patients. However, current methods for IL-2 detection are generally not sensitive to be used in clinic. This study aims to establish flow cytometry-based IL-2 detection as a feasible approach in determining IL-2 in peripheral blood of SLE patients.Methods: Flow cytometry was used to quantify the relative mean fluorescence intensity (MFI) of IL-2 in CD3+T cells and other lymphocyte subsets in peripheral blood mononuclear cell (PBMCs) from a cohort of 134 SLE patients and 112 healthy controls (HC). Correlations between IL-2 MFI and clinical or laboratory parameters in SLE patients were also investigated.Results: MFI of IL-2 represented IL-2 expression in CD3+T cells. IL-2 MFI was significantly lower in SLE patients compared to the HC group and negatively associated with anti-ribosomal protein antibodies, erythrocyte sedimentation rate (ESR), and blood urea. Conversely, it was positively correlated with IgA and hemoglobin. These associations with IgA, hemoglobin, ESR, and blood urea remained significant after adjusting for age and disease duration. IL-2 level was also positively correlated with the relative abundance of Th1, Th2, and Th17 cells. Furthermore, MFI of IL-2 recovered with effective treatment in SLE patients.Conclusions: MFI of IL-2 serves as a feasible marker of IL-2, which is significantly decreased in SLE patients and recovered with treatment, suggesting its potential for assessing short-term disease status and treatment response in SLE patients. Key Points • IL-2 MFI can be used to estimate IL-2 expression level in SLE patients. • IL-2 MFI is significantly reduced in SLE patients. • IL-2 MFI can serve as a marker for monitoring SLE activity and short-term status.","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-025-07478-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Low-dose interleukin 2 (IL-2) administration has been shown to selectively modulate regulatory T (Treg) cell abundance and alleviate the progression of systemic lupus erythematosus (SLE). IL-2 level could be indicator of low-dose IL-2 usage in SLE patients. However, current methods for IL-2 detection are generally not sensitive to be used in clinic. This study aims to establish flow cytometry-based IL-2 detection as a feasible approach in determining IL-2 in peripheral blood of SLE patients.

Methods: Flow cytometry was used to quantify the relative mean fluorescence intensity (MFI) of IL-2 in CD3⁺T cells and other lymphocyte subsets in peripheral blood mononuclear cell (PBMCs) from a cohort of 134 SLE patients and 112 healthy controls (HC). Correlations between IL-2 MFI and clinical or laboratory parameters in SLE patients were also investigated.

Results: MFI of IL-2 represented IL-2 expression in CD3⁺T cells. IL-2 MFI was significantly lower in SLE patients compared to the HC group and negatively associated with anti-ribosomal protein antibodies, erythrocyte sedimentation rate (ESR), and blood urea. Conversely, it was positively correlated with IgA and hemoglobin. These associations with IgA, hemoglobin, ESR, and blood urea remained significant after adjusting for age and disease duration. IL-2 level was also positively correlated with the relative abundance of Th1, Th2, and Th17 cells. Furthermore, MFI of IL-2 recovered with effective treatment in SLE patients.

Conclusions: MFI of IL-2 serves as a feasible marker of IL-2, which is significantly decreased in SLE patients and recovered with treatment, suggesting its potential for assessing short-term disease status and treatment response in SLE patients. Key Points • IL-2 MFI can be used to estimate IL-2 expression level in SLE patients. • IL-2 MFI is significantly reduced in SLE patients. • IL-2 MFI can serve as a marker for monitoring SLE activity and short-term status.

查看原文本刊更多论文

流式细胞术检测IL-2在系统性红斑狼疮中的意义。

目的：低剂量白介素2 （IL-2）可选择性调节调节性T （Treg）细胞丰度，缓解系统性红斑狼疮（SLE）的进展。IL-2水平可作为SLE患者低剂量使用IL-2的指标。然而，目前的IL-2检测方法普遍不够灵敏，不能用于临床。本研究旨在建立基于流式细胞术的IL-2检测方法，作为检测SLE患者外周血IL-2的可行方法。方法：采用流式细胞术定量测定134例SLE患者和112例健康对照（HC）外周血单个核细胞（PBMCs） CD3+T细胞和其他淋巴细胞亚群中IL-2的相对平均荧光强度（MFI）。研究还探讨了SLE患者IL-2 MFI与临床或实验室参数的相关性。结果：IL-2的MFI值代表了CD3+T细胞中IL-2的表达。与HC组相比，SLE患者IL-2 MFI显著降低，且与抗核糖体蛋白抗体、红细胞沉降率（ESR）和血尿素呈负相关。相反，与IgA和血红蛋白呈正相关。在调整了年龄和病程后，这些与IgA、血红蛋白、ESR和尿素的相关性仍然显著。IL-2水平也与Th1、Th2和Th17细胞的相对丰度呈正相关。此外，在SLE患者中，IL-2的MFI在有效治疗后恢复。结论：IL-2的MFI是一种可行的IL-2标志物，IL-2在SLE患者中显著降低，并在治疗后恢复，提示其在SLE患者中评估短期疾病状态和治疗反应的潜力。•IL-2 MFI可用于评估SLE患者IL-2表达水平。•IL-2 MFI在SLE患者中显著降低。•IL-2 MFI可作为监测SLE活动和短期状态的标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Rheumatology 医学-风湿病学

CiteScore

6.90

自引率

2.90%

发文量

441

审稿时长

3 months

期刊介绍： Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level. The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.